| Literature DB >> 33139585 |
Tae-Yong Choi1, Young Pyo Choi2, Ja Wook Koo1.
Abstract
Often called the second brain, the gut communicates extensively with the brain and vice versa. The conversation between these two organs affects a variety of physiological mechanisms that are associated with our mental health. Over the past decade, a growing body of evidence has suggested that the gut microbiome builds a unique ecosystem inside the gastrointestinal tract to maintain the homeostasis and that compositional changes in the gut microbiome are highly correlated with several mental disorders. There are ongoing efforts to treat or prevent mental disorders by regulating the gut microbiome using probiotics. These attempts are based on the seminal findings that probiotics can control the gut microbiome and affect mental conditions. However, some issues have yet to be conclusively addressed, especially the causality between the gut microbiome and mental disorders. In this review, we focus on the mechanisms by which the gut microbiome affects mental health and diseases. Furthermore, we discuss the potential use of probiotics as therapeutic agents for psychiatric disorders.Entities:
Keywords: Brain; Gastrointestinal microbiome; Mental disorders; Probiotics
Year: 2020 PMID: 33139585 PMCID: PMC7788310 DOI: 10.5607/en20047
Source DB: PubMed Journal: Exp Neurobiol ISSN: 1226-2560 Impact factor: 3.261
Gut dysbiosis observed in human patients with MDD
| Gut dysbiosis | References | Etc. | |
|---|---|---|---|
| ↓ | A-MDD | ||
| ↑ | |||
| ↓ | R-MDD | ||
| ↑ | |||
| ↓ | MDD-F | ||
| ↑ | |||
| ↓ | MDD-M | ||
| ↑ | |||
| ↑ | phylum Firmicutes | ||
| ↓ | phylum Bacteriodetes | ||
| ↑ | |||
↓, decreased compared to control; ↑, increased compared to control.
A-MDD, active-major depressive disorder; R-MDD, responded-major depressive disorder; MDD-F, female patients with MDD; MDD-M, male patients with MDD.
Duplicate bacteria are indicated in bold.
Gut dysbiosis observed in other human mental disorders
| Disorders | Gut dysbiosis | References | |
|---|---|---|---|
| Autism spectrum disorder (ASD) | ↓ | phylum | |
| ↑ | phylum Firmicutes | ||
| ↓ | |||
| ↑ | |||
| Alcoholism | ↑ | phylum | |
| ↓ | |||
| Alzheimer’s | |||
| disease (AD) | ↓ | phylum Firmicutes | |
| phylum Actinobacteria | |||
| ↑ | phylum | ||
↓, decreased compared to control; ↑, increased compared to control.
Fig. 1Communication between the gut and the brain and the relationship of gut dysbiosis and mental disorders.
Various behavioral changes observed in GF animals or by antibiotics-treated gut dysbiosis
| Behaviors | Changes | Animal models | Behavioral methods (references) |
|---|---|---|---|
| Basal locomotion | ↔ | GF | Open field test ( |
| ABX | Open field test ( | ||
| ↑ | GF | Open field test ( | |
| Anxiety | ↓ | GF | Open field test ( |
| Novelty suppressed feeding test ( | |||
| Light-dark test ( | |||
| Elevated plus maze test ( | |||
| ABX | Light-dark test ( | ||
| Elevated plus maze test ( | |||
| ↑ | GF | Open field test ( | |
| ↔ | GF | Light-dark test ( | |
| ABX | Open field test ( | ||
| Elevated plus maze test ( | |||
| Depression | ↓ | GF | Tail suspension test ( |
| Forced swim test ( | |||
| Sucrose preference test ( | |||
| ↑ | ABX | Forced swim test ( | |
| Tail suspension test ( | |||
| Social interaction | ↓ | GF | 3-chamber social interaction test ( |
| Social interaction test ( | |||
| ABX | 3-chamber social interaction test ( | ||
| ↑ | GF | 3-chamber social interaction test ( | |
| Cognition | ↓ | GF | Nobel object recognition test ( |
| T-maze test ( | |||
| ABX | Nobel object recognition test ( | ||
| Morris water maze test ( | |||
| ↔ | ABX | Barnez maze test ( | |
| Nobel object recognition test ( |
↔, no changes; ↑, increase; ↓, decrease; GF, germ-free animals; ABX, antibiotics.
*female only; **normal sociability, but reduced social novelty.
Probiotics used to treat mental disorders
| Disorders or models | Subjects | Probiotics | Suggested mechanisms | Ref. |
|---|---|---|---|---|
| Major depressive disorder (MDD) | Human | |||
| Mouse (CSDS) | ||||
| Mouse (CUS) | Regulating tryptophan-kynurenine pathway metabolites | |||
| Mouse (ELS) | Reducing serum corticosterone and inflammatory cytokines, increasing anti-inflammatory cytokines, modulating DA and 5-TH in PFC | |||
| Rat (CRS) | Reducing plasma stress hormones, regulating cytokines, and increasing hippocampal BDNF | |||
| Anxiety | Human | |||
| Human | ||||
| Human | Reducing plasma pro-inflammatory cytokines and increasing plasma anti-inflammatory cytokines, enhancing the serotonin pathway | |||
| Human (patients with chronic fatigue syndrome [CFS]) | ||||
| Mouse (ELS) | Reducing serum corticosterone and inflammatory cytokines, increasing anti-inflammatory cytokines, modulating DA and 5-TH in PFC | |||
| Rat (CRS) | Reducing plasma stress hormones, regulating cytokines, and increasing hippocampal BDNF | |||
| Autism spectrum disorder (ASD) | Mouse (shank3 KO) | Regulating GABA receptor and oxytocin expression | ||
| Mouse (shank3 KO, BTBR) | Redulating oxytocin expression | |||
| Alzheimer’s disease (AD) | Human | |||
| Mouse (3xTg) | SLAB51 ( | Reducing oxidative stress by activating SIRT-1 dependent mechanisms | ||
| Rat (b-amyloid injection) | ||||
| Social stress | Human |
CSDS, chronic social defeat stress; CUS, chronic unpredictable stress; ELS, early life stress; CRS, chronic restraint stress.